India to Saudi Arabia: Syringe Export Trade Route

The India to Saudi Arabia Syringe corridor is one of India's established pharmaceutical export routes, with 136 shipments documented worth a combined $16.1M USD. The route is dominated by GLAND PHARMA LTD, which alone accounts for roughly 53% of all export value, reflecting the consolidated nature of India's syringe manufacturing sector.

Across 13 active suppliers, the average shipment value stands at $118.0K USD — a figure that reflects both bulk commercial orders from large pharmaceutical companies and smaller specialty shipments. Sea freight dominates at 75% of all shipments, consistent with syringe's non-urgent bulk-order profile.

Shipment activity peaks during October–December, with an average transit time of 17 days port-to-port. The route has recorded an annual growth rate of 33.6%, placing it at rank #20 among India's top syringe export destinations globally.

On the import side, key buyers of Indian syringe in Saudi Arabia include BOSTON ONCOLOGY ARABIA, CONSIGNEE MENA SAUDI MEDICAL CO, MENA SAUDI MEDICAL CO.LTD, and 12 others. BOSTON ONCOLOGY ARABIA is the single largest importer with 95 shipments valued at $16.0M USD.

India's syringe exports to Saudi Arabia are driven primarily by a handful of large-scale manufacturers. GLAND PHARMA LTD with 53 shipments leads the pack, a pattern common in generic pharmaceutical corridors where manufacturing scale creates significant cost advantages. The presence of 13 active exporters signals a competitive but concentrated market — buyers in Saudi Arabia benefit from supplier diversity while the top tier handles the majority of volume.

The top 3 suppliers — GLAND PHARMA LTD, GLAND PHARMA LIMITED, ZYPHARS PHARMACEUTICS PRIVATE LIMITED — together account for 100% of total trade value on this route. The average shipment value of $118.0K USD reflects primarily bulk commercial orders from large pharmaceutical distributors.

Beyond the primary product category, shipments on this route include closely related formulations such as low molecular weight heparin enoxaparinsodium injection usp, 40mg in 0.4ml pre-filled syringe and low molecular weight heparin enoxaparinsodium injection usp,80mg in 0.8ml pre-filled syringe, suggesting that buyers in Saudi Arabia tend to consolidate orders across related product lines from the same Indian supplier.

On the buying side, BOSTON ONCOLOGY ARABIA is the largest importer with 95 shipments worth $16.0M USD — representing 100% of all syringe imports from India on this route. A total of 15 buyers are active on this corridor.